CytRx Corporation (NASDAQ: CYTR) today announced that its proprietary drug candidate INNO-206 dramatically inhibited tumor growth in an experimental animal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE